Bend Research to Present at the 2010 Annual Meeting and Exposition of the Controlled Release Society in Portland, Oregon
Published: Jul 09, 2010
BEND, Ore., July 9 /PRNewswire/ -- Bend Research Inc. (http://www.bendres.com) today announced that four of its scientists and researchers will present at the 37th Annual Meeting and Exposition of the Controlled Release Society.
Being held July 10-14, 2010 at the Oregon Convention Center in Portland, Oregon, the 2010 CRS meeting and exposition is one of the world's largest gatherings of industry experts in the field of controlled-release pharmaceuticals and medicines.
Bend Research is a leading independent drug-formulation company in the world, especially in the area of controlled-release and other drug delivery technologies. Many of the world's top pharmaceutical companies partner with Bend Research to assist them in identifying and developing the best solutions for creating new pharmaceutical medicines.
Representing Bend Research at the 2010 CRS meeting and exposition are:
- Brett Caldwell, Senior Research Chemist;
- David Vodak, Director of Research;
- Carey Bloom, Senior Research Chemist and Group Leader; and
- Ron Beyerinck, Senior Research Chemical Engineer.
Caldwell has been tapped by CRS as a Young Scientist Presenter. He will deliver a 45-minute talk on the opening day of the event, Saturday, July 10, at 3:30 p.m. on the topic "Spray-Dried Dispersions (SDDs) for Solubilization: Immediate and Controlled Release Applications."
Vodak will deliver a 15-minute talk on Monday, July 12, at 7 p.m. on the topic "Novel Engineered Particle Formulation for Inhaled PYY(3-36) and Demonstration of Appetite Suppression in a Mouse Model."
Bloom and Beyerinck will each present scientific posters at CRS 2010. Bloom's poster is entitled "Mucoadhesive Nanoparticles and Global Modeling for Topical Ocular Drug Delivery," and it will be presented on Monday, July 12 at 1 p.m. Beyerinck's poster is entitled "Melt-Spray-Congeal Microsphere Technology," and it will be presented on Tuesday, July 13 at 1 p.m.
"Bend Research appreciates the opportunity to update the industry at the CRS meeting," said Rod Ray, CEO of Bend Research. "We are grateful to our clients who provide us these opportunities to create new or improve existing medicines."
For more information about Bend Research and its value creation approach to drug-formulation and drug delivery systems, please contact Dana Settell at Bend Research at email@example.com or 541-382-4100.
About Bend Research Inc.
A world-leading independent drug formulation company, Bend Research has helped clients build greater value by creating new pharmaceuticals and drug-delivery systems for more than 30 years. Bend Research provides formulation and dosage-form support, assists in process development and optimization, manufactures clinical trial quantities of drug candidates in its cGMP facility, and advances promising drug candidates from conception through to commercialization. The company's flexible client-focused business model and collaborative approach to working with its customers result in long-term partnerships focused on value creation. Bend Research has more than 170 employees at its four state-of-the-art facilities in Bend, Oregon.
Dana Settell, Bend Research, 541-382-4100, firstname.lastname@example.org or
David Politis, Politis Communications, 801-523-3730 (work), 801-556-8184 (cell), email@example.com
SOURCE Bend Research Inc.